Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook

Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook

Regular price $7,495.00 Sale

Published on Jan 20, 2014 - 158 pages

The prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, its impact on the wider health economy is significant and there remains considerable unmet clinical need. Valued at US$10 billion and with a 5 year CAGR of 7.1% this high growth sector is set for radical change as new products and combinations are introduced changing both the treatment and competitive landscapes.

The cosy carve up of the market between Pfizer's Spiriva (tiotropium) and GSK's Advair/Serotide (fluticasone propionate/salmeterol), which currently account for 75% of sales globally, will be challenged by new entrants that provide better patient adherence, improve lung function, tackle inflammation and reduce exacerbations of the disease.

Why is COPD causing such excitement?

There is considerable industry and investor excitement about COPD treatment developments. Which of the new products will find favour with clinicians? What regulatory hurdles must they overcome? Do they offer a real clinical improvement over current therapies? Stripping away the hype and harnessing the real world insights from leading US and European KOL's, this Therapy Trends analysis critically examines the products and research and exposes the real potential. For example:
  • In September 2013, Novartis' Ultibro (glycopyrronium/indacaterol) was the first once daily fixed-dose LABA/LAMA to be approved, with promising research results and positive KOL opinion. However, approved dosages of the indacterol element may be lower in the US, which could affect efficacy and take up. Regulatory delay with the FDA is likely to hand the advantage GSK, Boehringer Ingelheim and Almirall/Forest all of whom are likely to bring LABA/LAMA combinations to the US market before Novartis.
  • In May 2013, GlaxoSmithKline's Breo/Relvar (fluticasone furoate/vilanterol), the first once-daily ICS/LABA was approved, but there are questions over whether it offers clinical value compared with Symbicort and Advair/Serodtide. However, the tide could turn if the product could become the first COPD therapy to gain a mortality claim if the outcome of the SUMMIT trial is positive. In the words of one KOL: "Let's assume that this study is positive. Then the whole field would change dramatically. This would cause an avalanche."
  • Takeda's Daxas/Daliresp (roflumilast) was the first, and remains the only, oral PDE-IV inhibitor available but sales are hampered by poor tolerability, unpleasant side effects, variable US formulary coverage and restrictions on use in some EU markets. Chiesi's CHF 6001 (Phase II) inhaled PDE-IV inhibitor is showing promising and is "extremely well tolerated in extended safety studies."
A Complete Ongoing Analysis of Current Trends, Future Forecasts and Landscape Modifiers

For instant access to an accurate, unbiased, qualitative review of the latest treatment trends along with a five-year quantitative COPD market forecast look no further than FirstWord's Therapy Trends: COPD. This comprehensive FirstWord research is available in two comprehensive modules:
  • The KOL Insight: COPD module provides a complete review and is enhanced with exclusive in-depth interviews with leading KOLs from the US and Europe.
  • The Consensus Outlook: COPD data analysis module provides annual historical and forecast product-level sales data from an average of leading equity analysts' projections. Key findings are provided in report which brings together data in charts and tables.
KOL Insight

KOL Insight Report
  • A qualitative analysis of the current and predicted treatment trends, clinical products and commercial changes in the global COPD market informed by in-depth expert views of leading clinicians
  • Compare the market's key players, products, late-stage pipeline drugs, product positioning, in the context of COPD market trends.
Event Bulletins
  • Benefit from the latest KOL views about significant event driven changes in COPD treatment trends.
Consensus Outlook

Consensus Report
  • An in-depth 5-year Consensus Outlook report of predicted quantitative changes in key COPD market forecast parameters drawn from 13 leading analyst and brokerage companies
  • Chart COPD market size, product sales, market share by company, competitive status and detailed market forecasts
Interactive Analytics File
  • Use the interactive Excel market analytics module of detailed market and product sales data from 2007 to 2017 to drill down and assess key company, market and product trends
Key Benefits

Therapy Trends KOL Insight: COPD analyses the current and predicted key issues, current products and late-stage pipeline products. The report gives you qualitative, inside information from exclusive FirstWord interviews with 12 key opinion leaders (KOLs) through the following:
  • KOL Insight Report - an in-depth analytical report on COPD treatment trends
  • Full report updates - issued to you after each and every significant COPD market event
  • Event Bulletins - the latest KOL views in response to each event
Key Report Features and Benefits
  • Critical insights on products and market developments from leading US and European clinicians
  • Complete coverage of all therapeutic approaches
  • Assessment of current leading COPD products by sub sector
  • Analysis of late-stage pipeline COPD therapies by sub sector
  • Competitive evaluation of leading players
  • Current thinking and trends in the treatment of COPD and emerging approaches such as Muscarinic antagonist/beta2 agonists
  • Predicted KOL treatment trends and market leaders
  • Ongoing clinical and market updates
All current therapeutic approaches covered
  • Long-acting muscarinic antagonists (LAMAs)
  • Long-acting beta2 agonists (LABAs)
  • Phosphodiesterase-IV (PDE-IV) inhibitors
  • Coverage of both their use as monotherapies or in combination
Expert Opinion for Real World Insights

The data and analysis in the report is enriched through the specific insights and opinions of leading clinicians working in COPD in the US and Europe. Their views on specific drugs and treatment pathways provide a unique front line perspective from those working in clinical setting. The results of these detailed and extensive interviews are incorporated though out the text so they can be read in the context of the issue or product being discussed.

Key Quotes from the Report